Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CMS wins FDA approval for autosegmentation software
According to the company, the Atlas-based autosegmentation (ABAS) is a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan.
According to the company, the Atlas-based autosegmentation (ABAS) is a software application that produces an estimate of the anatomy boundary contours needed to create a radiation treatment plan.
The test is marketed and sold by Qiagen. The new test is CE marked in Europe for in vitro diagnostic use and available for research use in other
The pivotal Azeptic trial is a randomized study evaluating the efficacy and safety of Zuragen injection in significantly reducing the incidence of catheter-related bloodstream infection in patients requiring
The patent describes and protects a muco-adhesive tablet for various applications in the field of opportunistic infections associated with AIDS and cancer. It has been validated in the
According to the company, Nplate, the first FDA-approved peptibody protein, works by raising and sustaining platelet counts, representing a novel approach for the long-term treatment of this chronic
Tests performed in the laboratories of AMP members have had a significant impact on the understanding and treatment of chronic conditions such as HIV, cancer, heart disease, diabetes,
King’s all-cash proposal is said to represent a 37% premium over the closing price of Alpharma common stock on August 21, 2008, the last trading day prior to
The net proceeds to Abiomed from the offering were approximately $41.7 million, after deducting the underwriting discount and estimated offering expenses. Morgan Stanley & Co was the sole
The clinical trial was a Phase IIb, randomized, placebo-controlled study of ATI-7505 in patients with chronic idiopathic constipation conducted at 42 trial sites in five countries. Patients were
The non-small cell lung cancer (NSCLC) trial is a randomized, multi-center, open-label Phase II study to evaluate the efficacy and safety of HGS-ETR1 in combination with carboplatin and